Anti-CCL11 Recombinant Antibody
•
0 likes•2 views
Recombinant human monoclonal antibody expressed in CHO binding to human CCL11. Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function. It was to be used to treat severe allergic disorders. https://www.creativebiolabs.net/Anti-CCL11-Therapeutic-Antibody-CAT-213-13558.htm
Report
Share
Report
Share
Download to read offline
Recommended
What is oncolytic virus
Recently, the development of molecular biotechnology allows modifications of viral genomes genetically and optimizes the transformation of available viruses with weak pathogenicity. These methods are used to enhance the oncolytic effect and reduce adverse reactions to maximize both efficacy and safety. Indeed, the oncolytic virus can stimulate a pro-inflammatory tumor environment by enhancing antigen recognition and robust immune responses. It overcomes the immune evasiveness and escape of malignant cells to eliminate the tumor cells.
https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
What is oncolytic virus therapy
An oncolytic virus is a form of promising therapeutic tool for the treatment of malignant tumors, which uses viruses to selectively infect and kill tumor cells and further to induce or boost specific antitumor immunity. https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
Reporter-encoding Oncolytic Virus
Oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests. Optical detection methods mainly include green fluorescent protein (GFP), enhanced GFP (eGFP), discosoma red fluorescent protein (DsRed), and bioluminescence imaging (BLI), which utilizes luciferases. Reporter-encoding oncolytic viruses, including vaccinia virus, adenovirus, herpes simplex virus and vesicular stomatitis virus, allow accurate tracking of gene expression, tumor metastases, viral infection as well as assessment of gene therapy.
https://www.creative-biolabs.com/oncolytic-virus/category-reporter-encoding-oncolytic-virus-293.htm
Pre-made Oncolytic VACV
Vaccinia virus can accommodate more than 30 kb of foreign DNA. Foreign genes can be stably integrated into the viral genome, resulting in efficient and long-term gene expression. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factors (VGF) results in enhanced tumor-selectively and antitumor activity, and reduced virus virulence. https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Pre-made Oncolytic Vaccinia Virus
Oncolytic viruses are a class of antitumor agents that selectively kill tumor cells without affecting normal cells. Vaccinia virus (VACV) is a large, enveloped virus that is considered as the most potential live biotherapeutic agent because of its strong oncolytic efficacy and potent antigen presentation capability that can combine well with its natural oncolytic activities for cancer immunotherapy. Many types of modified vaccinia virus have been used for in vitro and in vivo studies, as well as clinical trials.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Pre-made Oncolytic HSV
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Pre-made Oncolytic Herpes Simplex Virus
Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic Virus Delivery
Oncolytic viruses have the potential to powerfully and selectively kill cancer cells and have shown impressive efficacy in preclinical and clinical settings. However, their potential can be restricted by inefficient delivery into the complex tumor environment. Thus, the efficient delivery of oncolytic viruses remains a significant challenge in the field of oncology, limiting their therapeutic effect. https://www.creative-biolabs.com/oncolytic-virus/approaches-to-delivery-of-oncolytic-viruses.htm
Recommended
What is oncolytic virus
Recently, the development of molecular biotechnology allows modifications of viral genomes genetically and optimizes the transformation of available viruses with weak pathogenicity. These methods are used to enhance the oncolytic effect and reduce adverse reactions to maximize both efficacy and safety. Indeed, the oncolytic virus can stimulate a pro-inflammatory tumor environment by enhancing antigen recognition and robust immune responses. It overcomes the immune evasiveness and escape of malignant cells to eliminate the tumor cells.
https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
What is oncolytic virus therapy
An oncolytic virus is a form of promising therapeutic tool for the treatment of malignant tumors, which uses viruses to selectively infect and kill tumor cells and further to induce or boost specific antitumor immunity. https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
Reporter-encoding Oncolytic Virus
Oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests. Optical detection methods mainly include green fluorescent protein (GFP), enhanced GFP (eGFP), discosoma red fluorescent protein (DsRed), and bioluminescence imaging (BLI), which utilizes luciferases. Reporter-encoding oncolytic viruses, including vaccinia virus, adenovirus, herpes simplex virus and vesicular stomatitis virus, allow accurate tracking of gene expression, tumor metastases, viral infection as well as assessment of gene therapy.
https://www.creative-biolabs.com/oncolytic-virus/category-reporter-encoding-oncolytic-virus-293.htm
Pre-made Oncolytic VACV
Vaccinia virus can accommodate more than 30 kb of foreign DNA. Foreign genes can be stably integrated into the viral genome, resulting in efficient and long-term gene expression. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factors (VGF) results in enhanced tumor-selectively and antitumor activity, and reduced virus virulence. https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Pre-made Oncolytic Vaccinia Virus
Oncolytic viruses are a class of antitumor agents that selectively kill tumor cells without affecting normal cells. Vaccinia virus (VACV) is a large, enveloped virus that is considered as the most potential live biotherapeutic agent because of its strong oncolytic efficacy and potent antigen presentation capability that can combine well with its natural oncolytic activities for cancer immunotherapy. Many types of modified vaccinia virus have been used for in vitro and in vivo studies, as well as clinical trials.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Pre-made Oncolytic HSV
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Pre-made Oncolytic Herpes Simplex Virus
Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic Virus Delivery
Oncolytic viruses have the potential to powerfully and selectively kill cancer cells and have shown impressive efficacy in preclinical and clinical settings. However, their potential can be restricted by inefficient delivery into the complex tumor environment. Thus, the efficient delivery of oncolytic viruses remains a significant challenge in the field of oncology, limiting their therapeutic effect. https://www.creative-biolabs.com/oncolytic-virus/approaches-to-delivery-of-oncolytic-viruses.htm
Oncolytic Virus Application
Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy.
https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm
Oncolytic Virus Animal Model
To fully optimize oncolytic virotherapy and provide meaningful mechanistic insight, it is important to have representative animal models of oncolysis in various tumor types. https://www.creative-biolabs.com/oncolytic-virus/animal-models-for-oncolytic-virus-study.htm
Abciximab mechanism of action
Abciximab (also known as abcixifiban or c7E3 Fab), is the Fab fragment of the chimeric human-murine, monoclonal antibody 7E3. It is composed of murine variable regions and human constant regions.https://www.creativebiolabs.net/abciximab-overview.htm
Abagovomab mechanism of action
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). https://www.creativebiolabs.net/abagovomab-overview.htm
Wnt Pathway
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350-400 amino acids in length. Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated'.https://www.creativebiolabs.net/wnt-signaling-pathway.htm
TNF Pathway
TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm
TLR Pathway
Innate immune receptors, also known as pattern recognition receptors (PRRs), have been identified in the serum, on the cell surface, in endosomes, and in the cytoplasm. Toll-like receptors (TLRs) is one of the particularly important groups of PRRs.https://www.creativebiolabs.net/tlr-signal-pathway.htm
TGF-β Pathway
Transforming growth factor beta (TGF-β) is a cytokine that participates in both physiological and pathological processes.https://www.creativebiolabs.net/tgf-beta-signaling-pathway.htm
TCR Pathway
T-cell receptor (TCR) is a heterodimers composed of α and β peptide chains. TCR is mainly responsible for recognizing the antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).https://www.creativebiolabs.net/tcr-signal-pathway.htm
RAS Pathway
Ras, which is a low-molecular-weight GDP/GTP-binding guanine triphosphatase, is the prototypical member of the Ras superfamily of proteins. https://www.creativebiolabs.net/ras-signaling-pathway.htm
PPAR Pathway
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which are responsible for regulating gene expression.https://www.creativebiolabs.net/ppar-signaling-pathway.htm
VPI3K-AKT Pathway
PI3K-Akt signaling pathway is one of the important signal transduction pathways in cells. It is involved in regulating cell metabolism, growth, proliferation, survival, transcription and protein synthesis by affecting the activation of downstream effector molecules. https://www.creativebiolabs.net/pi3k-akt-signaling-pathway.htm
Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD19.
https://www.creativebiolabs.net/anti-cd19-adcc-enhanced-antibody-taplitumomab-105903.htm
Anti-CAIX/CA9 Recombinant Antibody
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
https://www.creativebiolabs.net/Anti-CAIX-CA9-Therapeutic-Antibody-Rencarex-13758.htm
Anti-B Cell Lymphomas Recombinant Antibody
Recombinant mouse monoclonal antibody expressed in CHO binding to human B-lymphoma cell. Detumomab is a mouse monoclonal antibody developed for the treatment of cancer.
https://www.creativebiolabs.net/Anti-B-cell-lymphomas-Therapeutic-Antibody-detumomab-326.htm
Anti-B. anthracis anthrax protective antigen
Recombinant monoclonal antibody to P. aeruginosa. Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against P. aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-Aerumab-11-13641.htm
Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)
Recombinant monoclonal antibody to Bacillus anthracis protective antigen. Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-ABthrax-13697.htm
Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human AFP. Tacatuzumab is a humanized monoclonal antibody intended for the treatment of cancer.
https://www.creativebiolabs.net/anti-afp-adcc-enhanced-antibody-tacatuzumab-105879.htm
Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22.
https://www.creativebiolabs.net/anti-cd22-adcc-enhanced-antibody-inotuzumab-105908.htm
Anti-Human MMP9 Recombinant Antibody
Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
https://www.creativebiolabs.net/Andecaliximab-67638.htm
“I’m still / I’m still / Chaining from the Block”
“An Outlook of the Ongoing and Future Relationship between Blockchain Technologies and Process-aware Information Systems.” Invited talk at the joint workshop on Blockchain for Information Systems (BC4IS) and Blockchain for Trusted Data Sharing (B4TDS), co-located with with the 36th International Conference on Advanced Information Systems Engineering (CAiSE), 3 June 2024, Limassol, Cyprus.
Uni Systems Copilot event_05062024_C.Vlachos.pdf
Unlocking Productivity: Leveraging the Potential of Copilot in Microsoft 365, a presentation by Christoforos Vlachos, Senior Solutions Manager – Modern Workplace, Uni Systems
More Related Content
More from Creative Biolabs
Oncolytic Virus Application
Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy.
https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm
Oncolytic Virus Animal Model
To fully optimize oncolytic virotherapy and provide meaningful mechanistic insight, it is important to have representative animal models of oncolysis in various tumor types. https://www.creative-biolabs.com/oncolytic-virus/animal-models-for-oncolytic-virus-study.htm
Abciximab mechanism of action
Abciximab (also known as abcixifiban or c7E3 Fab), is the Fab fragment of the chimeric human-murine, monoclonal antibody 7E3. It is composed of murine variable regions and human constant regions.https://www.creativebiolabs.net/abciximab-overview.htm
Abagovomab mechanism of action
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). https://www.creativebiolabs.net/abagovomab-overview.htm
Wnt Pathway
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350-400 amino acids in length. Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated'.https://www.creativebiolabs.net/wnt-signaling-pathway.htm
TNF Pathway
TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm
TLR Pathway
Innate immune receptors, also known as pattern recognition receptors (PRRs), have been identified in the serum, on the cell surface, in endosomes, and in the cytoplasm. Toll-like receptors (TLRs) is one of the particularly important groups of PRRs.https://www.creativebiolabs.net/tlr-signal-pathway.htm
TGF-β Pathway
Transforming growth factor beta (TGF-β) is a cytokine that participates in both physiological and pathological processes.https://www.creativebiolabs.net/tgf-beta-signaling-pathway.htm
TCR Pathway
T-cell receptor (TCR) is a heterodimers composed of α and β peptide chains. TCR is mainly responsible for recognizing the antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).https://www.creativebiolabs.net/tcr-signal-pathway.htm
RAS Pathway
Ras, which is a low-molecular-weight GDP/GTP-binding guanine triphosphatase, is the prototypical member of the Ras superfamily of proteins. https://www.creativebiolabs.net/ras-signaling-pathway.htm
PPAR Pathway
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which are responsible for regulating gene expression.https://www.creativebiolabs.net/ppar-signaling-pathway.htm
VPI3K-AKT Pathway
PI3K-Akt signaling pathway is one of the important signal transduction pathways in cells. It is involved in regulating cell metabolism, growth, proliferation, survival, transcription and protein synthesis by affecting the activation of downstream effector molecules. https://www.creativebiolabs.net/pi3k-akt-signaling-pathway.htm
Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD19.
https://www.creativebiolabs.net/anti-cd19-adcc-enhanced-antibody-taplitumomab-105903.htm
Anti-CAIX/CA9 Recombinant Antibody
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
https://www.creativebiolabs.net/Anti-CAIX-CA9-Therapeutic-Antibody-Rencarex-13758.htm
Anti-B Cell Lymphomas Recombinant Antibody
Recombinant mouse monoclonal antibody expressed in CHO binding to human B-lymphoma cell. Detumomab is a mouse monoclonal antibody developed for the treatment of cancer.
https://www.creativebiolabs.net/Anti-B-cell-lymphomas-Therapeutic-Antibody-detumomab-326.htm
Anti-B. anthracis anthrax protective antigen
Recombinant monoclonal antibody to P. aeruginosa. Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against P. aeruginosa. It is a fully human pentameric IgM antibody with a mouse J chain.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-Aerumab-11-13641.htm
Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)
Recombinant monoclonal antibody to Bacillus anthracis protective antigen. Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.
https://www.creativebiolabs.net/Anti-B-anthracis-anthrax-protective-antigen-PA-Therapeutic-Antibody-ABthrax-13697.htm
Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human AFP. Tacatuzumab is a humanized monoclonal antibody intended for the treatment of cancer.
https://www.creativebiolabs.net/anti-afp-adcc-enhanced-antibody-tacatuzumab-105879.htm
Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22.
https://www.creativebiolabs.net/anti-cd22-adcc-enhanced-antibody-inotuzumab-105908.htm
Anti-Human MMP9 Recombinant Antibody
Recombinant monoclonal antibody to MMP9. Andecaliximab is a human monoclonal antibody that can be potentially used in the treatment of Crohn's disease (CD), Colitis, ulcerative (UC), Solid tumors.
https://www.creativebiolabs.net/Andecaliximab-67638.htm
More from Creative Biolabs (20)
Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced
Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced
Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)
Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)
Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced
Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced
Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced
Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced
Recently uploaded
“I’m still / I’m still / Chaining from the Block”
“An Outlook of the Ongoing and Future Relationship between Blockchain Technologies and Process-aware Information Systems.” Invited talk at the joint workshop on Blockchain for Information Systems (BC4IS) and Blockchain for Trusted Data Sharing (B4TDS), co-located with with the 36th International Conference on Advanced Information Systems Engineering (CAiSE), 3 June 2024, Limassol, Cyprus.
Uni Systems Copilot event_05062024_C.Vlachos.pdf
Unlocking Productivity: Leveraging the Potential of Copilot in Microsoft 365, a presentation by Christoforos Vlachos, Senior Solutions Manager – Modern Workplace, Uni Systems
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
ABSTRACT: A prima vista, un mattoncino Lego e la backdoor XZ potrebbero avere in comune il fatto di essere entrambi blocchi di costruzione, o dipendenze di progetti creativi e software. La realtà è che un mattoncino Lego e il caso della backdoor XZ hanno molto di più di tutto ciò in comune.
Partecipate alla presentazione per immergervi in una storia di interoperabilità, standard e formati aperti, per poi discutere del ruolo importante che i contributori hanno in una comunità open source sostenibile.
BIO: Sostenitrice del software libero e dei formati standard e aperti. È stata un membro attivo dei progetti Fedora e openSUSE e ha co-fondato l'Associazione LibreItalia dove è stata coinvolta in diversi eventi, migrazioni e formazione relativi a LibreOffice. In precedenza ha lavorato a migrazioni e corsi di formazione su LibreOffice per diverse amministrazioni pubbliche e privati. Da gennaio 2020 lavora in SUSE come Software Release Engineer per Uyuni e SUSE Manager e quando non segue la sua passione per i computer e per Geeko coltiva la sua curiosità per l'astronomia (da cui deriva il suo nickname deneb_alpha).
Full-RAG: A modern architecture for hyper-personalization
Mike Del Balso, CEO & Co-Founder at Tecton, presents "Full RAG," a novel approach to AI recommendation systems, aiming to push beyond the limitations of traditional models through a deep integration of contextual insights and real-time data, leveraging the Retrieval-Augmented Generation architecture. This talk will outline Full RAG's potential to significantly enhance personalization, address engineering challenges such as data management and model training, and introduce data enrichment with reranking as a key solution. Attendees will gain crucial insights into the importance of hyperpersonalization in AI, the capabilities of Full RAG for advanced personalization, and strategies for managing complex data integrations for deploying cutting-edge AI solutions.
TrustArc Webinar - 2024 Global Privacy Survey
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
Fueling AI with Great Data with Airbyte Webinar
This talk will focus on how to collect data from a variety of sources, leveraging this data for RAG and other GenAI use cases, and finally charting your course to productionalization.
Removing Uninteresting Bytes in Software Fuzzing
Imagine a world where software fuzzing, the process of mutating bytes in test seeds to uncover hidden and erroneous program behaviors, becomes faster and more effective. A lot depends on the initial seeds, which can significantly dictate the trajectory of a fuzzing campaign, particularly in terms of how long it takes to uncover interesting behaviour in your code. We introduce DIAR, a technique designed to speedup fuzzing campaigns by pinpointing and eliminating those uninteresting bytes in the seeds. Picture this: instead of wasting valuable resources on meaningless mutations in large, bloated seeds, DIAR removes the unnecessary bytes, streamlining the entire process.
In this work, we equipped AFL, a popular fuzzer, with DIAR and examined two critical Linux libraries -- Libxml's xmllint, a tool for parsing xml documents, and Binutil's readelf, an essential debugging and security analysis command-line tool used to display detailed information about ELF (Executable and Linkable Format). Our preliminary results show that AFL+DIAR does not only discover new paths more quickly but also achieves higher coverage overall. This work thus showcases how starting with lean and optimized seeds can lead to faster, more comprehensive fuzzing campaigns -- and DIAR helps you find such seeds.
- These are slides of the talk given at IEEE International Conference on Software Testing Verification and Validation Workshop, ICSTW 2022.
AI-Powered Food Delivery Transforming App Development in Saudi Arabia.pdf
In this blog post, we'll delve into the intersection of AI and app development in Saudi Arabia, focusing on the food delivery sector. We'll explore how AI is revolutionizing the way Saudi consumers order food, how restaurants manage their operations, and how delivery partners navigate the bustling streets of cities like Riyadh, Jeddah, and Dammam. Through real-world case studies, we'll showcase how leading Saudi food delivery apps are leveraging AI to redefine convenience, personalization, and efficiency.
HCL Notes und Domino Lizenzkostenreduzierung in der Welt von DLAU
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-und-domino-lizenzkostenreduzierung-in-der-welt-von-dlau/
DLAU und die Lizenzen nach dem CCB- und CCX-Modell sind für viele in der HCL-Community seit letztem Jahr ein heißes Thema. Als Notes- oder Domino-Kunde haben Sie vielleicht mit unerwartet hohen Benutzerzahlen und Lizenzgebühren zu kämpfen. Sie fragen sich vielleicht, wie diese neue Art der Lizenzierung funktioniert und welchen Nutzen sie Ihnen bringt. Vor allem wollen Sie sicherlich Ihr Budget einhalten und Kosten sparen, wo immer möglich. Das verstehen wir und wir möchten Ihnen dabei helfen!
Wir erklären Ihnen, wie Sie häufige Konfigurationsprobleme lösen können, die dazu führen können, dass mehr Benutzer gezählt werden als nötig, und wie Sie überflüssige oder ungenutzte Konten identifizieren und entfernen können, um Geld zu sparen. Es gibt auch einige Ansätze, die zu unnötigen Ausgaben führen können, z. B. wenn ein Personendokument anstelle eines Mail-Ins für geteilte Mailboxen verwendet wird. Wir zeigen Ihnen solche Fälle und deren Lösungen. Und natürlich erklären wir Ihnen das neue Lizenzmodell.
Nehmen Sie an diesem Webinar teil, bei dem HCL-Ambassador Marc Thomas und Gastredner Franz Walder Ihnen diese neue Welt näherbringen. Es vermittelt Ihnen die Tools und das Know-how, um den Überblick zu bewahren. Sie werden in der Lage sein, Ihre Kosten durch eine optimierte Domino-Konfiguration zu reduzieren und auch in Zukunft gering zu halten.
Diese Themen werden behandelt
- Reduzierung der Lizenzkosten durch Auffinden und Beheben von Fehlkonfigurationen und überflüssigen Konten
- Wie funktionieren CCB- und CCX-Lizenzen wirklich?
- Verstehen des DLAU-Tools und wie man es am besten nutzt
- Tipps für häufige Problembereiche, wie z. B. Team-Postfächer, Funktions-/Testbenutzer usw.
- Praxisbeispiele und Best Practices zum sofortigen Umsetzen
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Are you ready to revolutionize how you handle data? Join us for a webinar where we’ll bring you up to speed with the latest advancements in Generative AI technology and discover how leveraging FME with tools from giants like Google Gemini, Amazon, and Microsoft OpenAI can supercharge your workflow efficiency.
During the hour, we’ll take you through:
Guest Speaker Segment with Hannah Barrington: Dive into the world of dynamic real estate marketing with Hannah, the Marketing Manager at Workspace Group. Hear firsthand how their team generates engaging descriptions for thousands of office units by integrating diverse data sources—from PDF floorplans to web pages—using FME transformers, like OpenAIVisionConnector and AnthropicVisionConnector. This use case will show you how GenAI can streamline content creation for marketing across the board.
Ollama Use Case: Learn how Scenario Specialist Dmitri Bagh has utilized Ollama within FME to input data, create custom models, and enhance security protocols. This segment will include demos to illustrate the full capabilities of FME in AI-driven processes.
Custom AI Models: Discover how to leverage FME to build personalized AI models using your data. Whether it’s populating a model with local data for added security or integrating public AI tools, find out how FME facilitates a versatile and secure approach to AI.
We’ll wrap up with a live Q&A session where you can engage with our experts on your specific use cases, and learn more about optimizing your data workflows with AI.
This webinar is ideal for professionals seeking to harness the power of AI within their data management systems while ensuring high levels of customization and security. Whether you're a novice or an expert, gain actionable insights and strategies to elevate your data processes. Join us to see how FME and AI can revolutionize how you work with data!
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
20240605 QFM017 Machine Intelligence Reading List May 2024
Everything I found interesting about machines behaving intelligently during May 2024
OpenID AuthZEN Interop Read Out - Authorization
During Identiverse 2024 and EIC 2024, members of the OpenID AuthZEN WG got together and demoed their authorization endpoints conforming to the AuthZEN API
National Security Agency - NSA mobile device best practices
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
Microsoft - Power Platform_G.Aspiotis.pdf
Revolutionizing Application Development
with AI-powered low-code, presentation by George Aspiotis, Sr. Partner Development Manager, Microsoft
20240607 QFM018 Elixir Reading List May 2024
Everything I found interesting about the Elixir programming ecosystem in May 2024
Choosing The Best AWS Service For Your Website + API.pptx
Have you ever been confused by the myriad of choices offered by AWS for hosting a website or an API?
Lambda, Elastic Beanstalk, Lightsail, Amplify, S3 (and more!) can each host websites + APIs. But which one should we choose?
Which one is cheapest? Which one is fastest? Which one will scale to meet our needs?
Join me in this session as we dive into each AWS hosting service to determine which one is best for your scenario and explain why!
Recently uploaded (20)
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Full-RAG: A modern architecture for hyper-personalization
Full-RAG: A modern architecture for hyper-personalization
AI-Powered Food Delivery Transforming App Development in Saudi Arabia.pdf
AI-Powered Food Delivery Transforming App Development in Saudi Arabia.pdf
HCL Notes und Domino Lizenzkostenreduzierung in der Welt von DLAU
HCL Notes und Domino Lizenzkostenreduzierung in der Welt von DLAU
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdf
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
National Security Agency - NSA mobile device best practices
National Security Agency - NSA mobile device best practices
Choosing The Best AWS Service For Your Website + API.pptx
Choosing The Best AWS Service For Your Website + API.pptx